Generic Celebrex is coming

Share this article:

Teva and Pfizer have settled their Celebrex spat. Teva said in a statement Thursday that the settlement means generics of the pain med in 50mg, 100mg, 200mg and 400mg doses can hit the marketplace in December.

Last year's $3 billion in Celebrex sales represented a 7% increase in worldwide sales compared to 2012, largely supported by price increases and growth in the US.

Pfizer's fight to protect a 2015 patent extension ended last month when a court ruled a patent invalid.

Morningstar analyst Damien Conover told Reuters at the time he expected generics could cost Pfizer $1 billion in 2014.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.